Aimee Vaccine Co., Ltd. announced that its adsorbed tetanus vaccine has officially submitted a clinical trial application to the Drug Evaluation Center (CDE) of China National Pharmaceutical Administration in August 2024. This is part of the company's product development strategy, aiming to promote the development of multi-valent vaccines and enhance the company's industry position in the domestic second-class vaccine field. Aimee Vaccine is also actively developing quadrivalent vaccines and is expected to submit relevant clinical trial applications starting in 2024 to prevent multiple diseases. According to the data from Zhaoshi Consulting, the market size of domestic multi-valent vaccines is expected to reach RMB 9.572 billion in 2030, and these research and development activities of Aimee Vaccine will contribute to the company's long-term development.

Aimee Vaccine Co., Ltd. announced that its adsorbed tetanus vaccine has officially submitted a clinical trial application to the Drug Evaluation Center (CDE) of China National Pharmaceutical Administration in August 2024. This is part of the company's product development strategy, aiming to promote the development of multi-valent vaccines and enhance the company's industry position in the domestic second-class vaccine field. Aimee Vaccine is also actively developing quadrivalent vaccines and is expected to submit relevant clinical trial applications starting in 2024 to prevent multiple diseases. According to the data from Zhaoshi Consulting, the market size of domestic multi-valent vaccines is expected to reach RMB 9.572 billion in 2030, and these research and development activities of Aimee Vaccine will contribute to the company's long-term development.